Haploidentical vs Matched Unrelated Donor Age Impacts Survival in Patients With ALL
Researchers sought to determine the impact of donor age on survival in patients with ALL who undergo HCT with PTCy for GVHD prophylaxis.
Diagnosis & Disease Information
FDA Issues Complete Response Letter for Ruxolitinib Extended-Release Tablets
The letter states that the application cannot be approved in its present form.
T-Cell Subset Linked With Survival After Haplo-HCT for Acute Myeloid Leukemia
Researchers sought to determine whether greater Vδ2-positive T-cell recovery would impact mortality for patients with AML who undergo haplo-HCT.
Persistent Organ Damage Common One Year After COVID-19
59 percent of individuals had organ impairment at one year; breathlessness, cognitive dysfunction, poor HRQoL also common.
Mega-Dose Decitabine May Improve Conditioning Before Allo-HSCT in AML
Researchers sought to determine whether a larger dose of decitabine prior to allo-HSCT would improve outcomes in patients with AML.
Orca-T Improves Allo-HSCT Outcomes Compared With Historical Control
Researchers sought to determine whether Orca-T could improve relapse and survival outcomes compared with historical controls for patients receiving allo-HSCT.
Promising Prophylactic Efficacy With RGI-2001 Plus Standard of Care for Acute GVHD
Researchers sought to determine whether adding RGI-2001 to a calcineurin inhibitor and methotrexate or mycophenolate mofetil would help prevent acute GVHD.
Calcineurin Inhibitor-Free Prophylaxis Associated With Shorter Time to Immunosuppression Withdrawal, GVHD
Researchers assessed whether PTCy with sirolimus would reduce median time to immunosuppression withdrawal and a lower rate of chronic GVHD following allo-HCT.
Itacitinib Is an Effective Treatment for Acute GVHD
Researchers sought to determine whether itacitinib would be an effective treatment for acute GVHD through a multicenter, phase 2 trial.
Ibrutinib Failed to Improve Outcomes in Previously Untreated Chronic GVHD
Researchers sought to determine whether ibrutinib could improve outcomes in the frontline setting of cGVHD.
- Loading...
Loading...
Next post in General Hematology
Loading... 
Loading...